Načítá se...
Five-Year Survival Among Stage IIIA Lung Cancer Patients Receiving Two Different Treatment Modalities
BACKGROUND: Five-year survival rates among stage IIIA lung cancer patients range between 2% and 15%, and there is currently no consensus regarding optimal treatment approaches for these patients. The current investigation evaluated survival outcomes among stage IIIA lung cancer patients receiving 2...
Uloženo v:
| Vydáno v: | Med Sci Monit |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
International Scientific Literature, Inc.
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5017688/ https://ncbi.nlm.nih.gov/pubmed/27442604 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12659/MSM.898675 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|